Lindbrook Capital, LLC Allakos Inc. Transaction History

Lindbrook Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	SELL	$2.13 - $5.55 $1,199 - $3,124	-563 Reduced 83.66%	110 $0
Q2 2023 Jul 28, 2023	SELL	$3.6 - $5.25 $3,596 - $5,244	-999 Reduced 59.75%	673 $2,000
Q1 2023 Apr 26, 2023	BUY	$4.3 - $8.27 $5,138 - $9,882	1,195 Added 250.52%	1,672 $7,000
Q4 2022 Jan 24, 2023	BUY	$5.66 - $8.42 $752 - $1,119	133 Added 38.66%	477 $0
Q3 2022 Nov 10, 2022	BUY	$3.02 - $6.12 $1,038 - $2,105	344 New	344 $2,000
Q1 2022 Apr 21, 2022	SELL	$5.08 - $9.81 $746 - $1,442	-147 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$8.55 - $111.89 $85 - $1,118	10 Added 7.3%	147 $1,000
Q2 2021 Jul 27, 2021	SELL	$85.37 - $114.1 $597 - $798	-7 Reduced 4.86%	137 $12,000
Q1 2021 Apr 28, 2021	BUY	$109.73 - $153.66 $768 - $1,075	7 Added 5.11%	144 $17,000
Q2 2020 Jul 27, 2020	BUY	$44.04 - $80.69 $1,805 - $3,308	41 Added 42.71%	137 $10,000
Q1 2020 Apr 22, 2020	BUY	$44.49 - $93.39 $4,271 - $8,965	96 New	96 $4,000

66M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $22M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.